Evolution of the Average Target: ORIC Pharmaceuticals, Inc.

Evolution of the Target Price: ORIC Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ORIC Pharmaceuticals, Inc.

59c22c4.JqsyPvTyKd4EVkCbWTnLWJ9h8M6yuFJYUVEtafsy8pI.RMRiVZOGeZZObyHyC2OfFeYMx7mCzyMvNTdpIbgGwf1zyEt2pqpOuDdnLw~6ff147e74cf7910595228db113aab8f5
04-01 Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating MT
01-07 Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target MT
11-14 Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $15 From $12, Maintains Outperform Rating MT
25-05-06 Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating MT
24-10-31 JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target MT
24-10-31 Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target MT
24-09-06 Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals With Buy Rating, $20 Price Target MT
24-08-13 Oppenheimer Adjusts ORIC Pharmaceuticals Price Target to $15 From $17, Maintains Outperform Rating MT
24-03-27 JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating MT
24-03-21 HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating MT
24-03-12 Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating MT
24-03-01 Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating MT
24-02-26 Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating MT
23-12-13 HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating MT
23-12-12 Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating MT
23-10-26 HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating MT
23-10-24 JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating MT
23-10-23 Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating MT
23-09-22 Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities MT
23-08-16 Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating MT
23-08-15 HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating MT
23-05-10 HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating MT
23-04-05 Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating MT
23-03-23 HC Wainwright Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $16 MT
23-03-21 Guggenheim Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $15 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+59.1%
+18.83%
+12.23%
+16.45%
+64.33%
+18.32%
-3.81%
+14.38%
+24.38%
-1.74%
Average +22.25%
Weighted average by Cap. +19.10%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
12.89USD
Average target price
20.67USD
Spread / Average Target
+60.33%
High Price Target
27.00USD
Spread / Highest target
+109.46%
Low Price Target
14.00USD
Spread / Lowest Target
+8.61%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ORIC Stock
  4. Consensus ORIC Pharmaceuticals, Inc.